[1] |
SAKAGUCHI S, SAKAGUCHI N, ASANO M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). breakdown of a single mechanism of self-tolerance causes various autoimmune diseases[J]. J Immunol, 1995, 155(3): 1151-1164. DOI: 10.4049/jimmunol.155.3.1151.
|
[2] |
HORI S, NOMURA T, SAKAGUCHI S. Control of regulatory T cell development by the transcription factor Foxp3[J]. Science, 2003, 299(5609): 1057-1061. DOI: 10.1126/science.1079490.
|
[3] |
SAKAGUCHI S. Taking regulatory T cells into medicine[J]. J Exp Med, 2021, 218(6): e20210831. DOI: 10.1084/jem.20210831.
|
[4] |
WHANGBO JS, NIKIFOROW S, KIM HT, et al. A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease[J]. Blood Adv, 2022, 6(21): 5786-5796. DOI: 10.1182/bloodadvances.2021006625.
|
[5] |
LAPP MM, LIN G, KOMIN A, et al. Modeling the potential of Treg-based therapies for transplant rejection: effect of dose, timing, and accumulation site[J]. Transpl Int, 2022, 35: 10297. DOI: 10.3389/ti.2022.10297.
|
[6] |
石炳毅, 陈文, 刘志佳. 调节性免疫细胞在异种移植免疫中的作用[J]. 器官移植, 2020, 11(3): 321-325. DOI: 10.3969/j.issn.1674-7445.2020.03.001.SHI BY, CHEN W, LIU ZJ. The function of regulatory immunological cell in xenotransplantation immunity[J]. Organ Transplant, 2020, 11(3): 321-325. DOI: 10.3969/j.issn.1674-7445.2020.03.001.
|
[7] |
轩娟娟, 白鸿太, 张继翔, 等. 调节性T细胞亚群在肝移植中的作用及临床应用进展[J]. 中国组织工程研究, 2022, 26(7): 1143-1148.XUAN JJ, BAI HT, ZHANG JX, et al. Role of regulatory T cell subsets in liver transplantation and progress in clinical application[J]. Chin J Tissue Eng Res, 2022, 26(7): 1143-1148.
|
[8] |
VAN DER VEEKEN J, CAMPBELL C, PRITYKIN Y, et al. Genetic tracing reveals transcription factor Foxp3-dependent and Foxp3-independent functionality of peripherally induced Treg cells[J]. Immunity, 2022, 55(7): 1173-1184. DOI: 10.1016/j.immuni.2022.05.010.
|
[9] |
OHKURA N, SAKAGUCHI S. Transcriptional and epigenetic basis of Treg cell development and function: its genetic anomalies or variations in autoimmune diseases[J]. Cell Res, 2020, 30(6): 465-474. DOI: 10.1038/s41422-020-0324-7.
|
[10] |
FERREIRA RC, SIMONS HZ, THOMPSON WS, et al. Cells with Treg-specific Foxp3 demethylation but low CD25 are prevalent in autoimmunity[J]. J Autoimmun, 2017, 84: 75-86. DOI: 10.1016/j.jaut.2017.07.009.
|
[11] |
MIYARA M, YOSHIOKA Y, KITOH A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the Foxp3 transcription factor[J]. Immunity, 2009, 30(6): 899-911. DOI: 10.1016/j.immuni.2009.03.019.
|
[12] |
BROWN ME, PETERS LD, HANBALI SR, et al. Human CD4+CD25+CD226- Tregs demonstrate increased purity, lineage stability, and suppressive capacity versus CD4+CD25+CD127lo/- Tregs for adoptive cell therapy[J]. Front Immunol, 2022, 13: 873560. DOI: 10.3389/fimmu.2022.873560.
|
[13] |
LAM AJ, UDAY P, GILLIES JK, et al. Helios is a marker, not a driver, of human Treg stability[J]. Eur J Immunol, 2022, 52(1): 75-84. DOI: 10.1002/eji.202149318.
|
[14] |
SO L, OBATA-NINOMIYA K, HU A, et al. Regulatory T cells suppress CD4+ effector T cell activation by controlling protein synthesis[J]. J Exp Med, 2023, 220(3): e20221676. DOI: 10.1084/jem.20221676.
|
[15] |
KURELIC R, KRIEG PF, SONNER JK, et al. Upregulation of phosphodiesterase 2A augments T cell activation by changing cGMP/cAMP cross-talk[J]. Front Pharmacol, 2021, 12: 748798. DOI: 10.3389/fphar.2021.748798.
|
[16] |
LEGOUX FP, LIM JB, CAULEY AW, et al. CD4+ T cell tolerance to tissue-restricted self antigens is mediated by antigen-specific regulatory T cells rather than deletion[J]. Immunity, 2015, 43(5): 896-908. DOI: 10.1016/j.immuni.2015.10.011.
|
[17] |
ESKANDARI SK, SULKAJ I, MELO MB, et al. Regulatory T cells engineered with TCR signaling-responsive IL-2 nanogels suppress alloimmunity in sites of antigen encounter[J]. Sci Transl Med, 2020, 12(569): eaaw4744. DOI: 10.1126/scitranslmed.aaw4744.
|
[18] |
GOTOT J, DHANA E, YAGITA H, et al. Antigen-specific Helios- , Neuropilin-1- Tregs induce apoptosis of autoreactive B cells via PD-L1[J]. Immunol Cell Biol, 2018, 96(8): 852-862. DOI: 10.1111/imcb.12053.
|
[19] |
ZHANG Y, MAKSIMOVIC J, NASELLI G, et al. Genome-wide DNA methylation analysis identifies hypomethylated genes regulated by Foxp3 in human regulatory T cells[J]. Blood, 2013, 122(16): 2823-2836. DOI: 10.1182/blood-2013-02-481788.
|
[20] |
MANIERI NA, CHIANG EY, GROGAN JL. TIGIT: a key inhibitor of the cancer immunity cycle[J]. Trends Immunol, 2017, 38(1): 20-28. DOI: 10.1016/j.it.2016.10.002.
|
[21] |
BÉZIE S, FREUCHET A, SÉRAZIN C, et al. IL-34 actions on Foxp3+ Tregs and CD14+ monocytes control human graft rejection[J]. Front Immunol, 2020, 11: 1496. DOI: 10.3389/fimmu.2020.01496.
|
[22] |
FIYOUZI T, PELAEZ-PRESTEL HF, REYES-MANZANAS R, et al. Enhancing regulatory T cells to treat inflammatory and autoimmune diseases[J]. Int J Mol Sci, 2023, 24(9): 7797. DOI: 10.3390/ijms24097797.
|
[23] |
SAWITZKI B, HARDEN PN, REINKE P, et al. Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials[J]. Lancet, 2020, 395(10237): 1627-1639. DOI: 10.1016/S0140-6736(20)30167-7.
|
[24] |
JOFFRE O, GORSSE N, ROMAGNOLI P, et al. Induction of antigen-specific tolerance to bone marrow allografts with CD4+CD25+ T lymphocytes[J]. Blood, 2004, 103(11): 4216-4221. DOI: 10.1182/blood-2004-01-0005.
|
[25] |
MARTIN-MORENO PL, TRIPATHI S, CHANDRAKER A. Regulatory T cells and kidney transplantation[J]. Clin J Am Soc Nephrol, 2018, 13(11): 1760-1764. DOI: 10.2215/CJN.01750218.
|
[26] |
LAVAZZA C, BUDELLI S, MONTELATICI E, et al. Process development and validation of expanded regulatory T cells for prospective applications: an example of manufacturing a personalized advanced therapy medicinal product[J]. J Transl Med, 2022, 20(1): 14. DOI: 10.1186/s12967-021-03200-x.
|
[27] |
FRASER H, SAFINIA N, GRAGEDA N, et al. A rapamycin-based GMP-compatible process for the isolation and expansion of regulatory T cells for clinical trials[J]. Mol Ther Methods Clin Dev, 2018, 8: 198-209. DOI: 10.1016/j.omtm.2018.01.006.
|
[28] |
BAETEN P, VAN ZEEBROECK L, KLEINEWIETFELD M, et al. Improving the efficacy of regulatory T cell therapy[J]. Clin Rev Allergy Immunol, 2022, 62(2): 363-381. DOI: 10.1007/s12016-021-08866-1.
|
[29] |
BROOK MO, HESTER J, PETCHEY W, et al. Transplantation Without Overimmunosuppression (TWO) study protocol: a phase 2b randomised controlled single-centre trial of regulatory T cell therapy to facilitate immunosuppression reduction in living donor kidney transplant recipients[J]. BMJ Open, 2022, 12(4): e061864. DOI: 10.1136/bmjopen-2022-061864.
|
[30] |
HARDEN PN, GAME DS, SAWITZKI B, et al. Feasibility, long-term safety, and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients[J]. Am J Transplant, 2021, 21(4): 1603-1611. DOI: 10.1111/ajt.16395.
|
[31] |
HARRIS F, BERDUGO YA, TREE T. IL-2-based approaches to Treg enhancement[J]. Clin Exp Immunol, 2023, 211(2): 149-163. DOI: 10.1093/cei/uxac105.
|
[32] |
KOLIOS AGA, TSOKOS GC, KLATZMANN D. Interleukin-2 and regulatory T cells in rheumatic diseases[J]. Nat Rev Rheumatol, 2021, 17(12): 749-766. DOI: 10.1038/s41584-021-00707-x.
|
[33] |
KIM HT, KORETH J, WHANGBO J, et al. Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease[J]. Blood Adv, 2022, 6(15): 4392-4402. DOI: 10.1182/bloodadvances.2022007773.
|
[34] |
WHANGBO JS, KIM HT, MIRKOVIC N, et al. Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children[J]. Blood Adv, 2019, 3(17): 2550-2561. DOI: 10.1182/bloodadvances.2019000631.
|
[35] |
MEGURI Y, ASANO T, YOSHIOKA T, et al. Responses of regulatory and effector T-cells to low-dose interleukin-2 differ depending on the immune environment after allogeneic stem cell transplantation[J]. Front Immunol, 2022, 13: 891925. DOI: 10.3389/fimmu.2022.891925.
|
[36] |
ZHOU P. Emerging mechanisms and applications of low-dose IL-2 therapy in autoimmunity[J]. Cytokine Growth Factor Rev, 2022, 67: 80-88. DOI: 10.1016/j.cytogfr.2022.06.003.
|
[37] |
WILSON MS, PESCE JT, RAMALINGAM TR, et al. Suppression of murine allergic airway disease by IL-2: anti-IL-2 monoclonal antibody-induced regulatory T cells[J]. J Immunol, 2008, 181(10): 6942-6954. DOI: 10.4049/jimmunol.181.10.6942.
|
[38] |
WING JB, TANAKA A, SAKAGUCHI S. Human Foxp3+ regulatory T cell heterogeneity and function in autoimmunity and cancer[J]. Immunity, 2019, 50(2): 302-316. DOI: 10.1016/j.immuni.2019.01.020.
|
[39] |
HU M, HAWTHORNE WJ, NICHOLSON L, et al. Low-dose interleukin-2 combined with rapamycin led to an expansion of CD4+CD25+Foxp3+ regulatory T cells and prolonged human islet allograft survival in humanized mice[J]. Diabetes, 2020, 69(8): 1735-1748. DOI: 10.2337/db19-0525.
|
[40] |
ZHANG B, SUN J, WANG Y, et al. Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells[J]. Nat Biomed Eng, 2021, 5(11): 1288-1305. DOI: 10.1038/s41551-021-00797-8.
|
[41] |
MURAKAMI N, BORGES TJ, WIN TS, et al. Low-dose interleukin-2 promotes immune regulation in face transplantation: a pilot study[J]. Am J Transplant, 2023, 23(4): 549-558. DOI: 10.1016/j.ajt.2023.01.016.
|
[42] |
MCGOVERN J, HOLLER A, THOMAS S, et al. Forced Foxp3 expression can improve the safety and antigen-specific function of engineered regulatory T cells[J]. J Autoimmun, 2022, 132: 102888. DOI: 10.1016/j.jaut.2022.102888.
|
[43] |
BLUESTONE JA, TANG Q. Treg cells-the next frontier of cell therapy[J]. Science, 2018, 362(6411): 154-155. DOI: 10.1126/science.aau2688.
|
[44] |
FERREIRA LMR, MULLER YD, BLUESTONE JA, et al. Next-generation regulatory T cell therapy[J]. Nat Rev Drug Discov, 2019, 18(10): 749-769. DOI: 10.1038/s41573-019-0041-4.
|
[45] |
HU M, ROGERS NM, LI J, et al. Antigen specific regulatory T cells in kidney transplantation and other tolerance settings[J]. Front Immunol, 2021, 12: 717594. DOI: 10.3389/fimmu.2021.717594.
|
[46] |
PUTNAM AL, SAFINIA N, MEDVEC A, et al. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation[J]. Am J Transplant, 2013, 13(11): 3010-3020. DOI: 10.1111/ajt.12433.
|
[47] |
TRIPATHI S, MARTIN-MORENO PL, KAVALAM G, et al. Adenosinergic pathway and linked suppression: two critical suppressive mechanisms of human donor antigen specific regulatory T cell lines expanded post transplant[J]. Front Immunol, 2022, 13: 849939. DOI: 10.3389/fimmu.2022.849939.
|
[48] |
SANDERS JM, JEYAMOGAN S, MATHEW JM, et al. Foxp3+ regulatory T cell therapy for tolerance in autoimmunity and solid organ transplantation[J]. Front Immunol, 2022, 13: 1055466. DOI: 10.3389/fimmu.2022.1055466.
|
[49] |
YANG SJ, SINGH AK, DROW T, et al. Pancreatic islet-specific engineered Tregs exhibit robust antigen-specific and bystander immune suppression in type 1 diabetes models[J]. Sci Transl Med, 2022, 14(665): eabn1716. DOI: 10.1126/scitranslmed.abn1716.
|
[50] |
RANA J, BISWAS M. Regulatory T cell therapy: current and future design perspectives[J]. Cell Immunol, 2020, 356: 104193. DOI: 10.1016/j.cellimm.2020.104193.
|
[51] |
FRITSCHE E, VOLK HD, REINKE P, et al. Toward an optimized process for clinical manufacturing of CAR-Treg cell therapy[J]. Trends Biotechnol, 2020, 38(10): 1099-1112. DOI: 10.1016/j.tibtech.2019.12.009.
|
[52] |
吴俣, 李佩璐, 葛军, 等. 嵌合抗原受体调节性T细胞免疫疗法在器官移植中的应用[J]. 器官移植, 2020, 11(5): 547-552. DOI: 10.3969/j.issn.1674-7445.2020.05.003.WU Y, LI PL, GE J, et al. Application of chimeric antigen receptor-regulatory T cell immunotherapy in organ transplantation[J]. Organ Transplant, 2020, 11(5): 547-552. DOI: 10.3969/j.issn.1674-7445.2020.05.003.
|
[53] |
MULLER YD, FERREIRA LMR, RONIN E, et al. Precision engineering of an anti-HLA-A2 chimeric antigen receptor in regulatory T cells for transplant immune tolerance[J]. Front Immunol, 2021, 12: 686439. DOI: 10.3389/fimmu.2021.686439.
|
[54] |
BOROUGHS AC, LARSON RC, CHOI BD, et al. Chimeric antigen receptor costimulation domains modulate human regulatory T cell function[J]. JCI Insight, 2019, 5(8): e126194. DOI: 10.1172/jci.insight.126194.
|
[55] |
BOLIVAR-WAGERS S, LARSON JH, JIN S, et al. Cytolytic CD4+ and CD8+ regulatory T-cells and implications for developing immunotherapies to combat graft-versus-host disease[J]. Front Immunol, 2022, 13: 864748. DOI: 10.3389/fimmu.2022.864748.
|
[56] |
张温乐, 于怡萌, 雷轶, 等. 调节性T细胞免疫疗法在自身免疫疾病治疗和移植免疫中的应用[J]. 药学进展, 2023, 47(1): 35-42. DOI: 10.20053/j.issn1001-5094.2023.01.004.ZHANG WL, YU YM, LEI Y, et al. Application of Treg cell immunotherapy in the treatment of autoimmune diseases and transplantation immunity[J]. Prog Pharm Sci, 2023, 47(1): 35-42. DOI: 10.20053/j.issn1001-5094.2023.01.004.
|
[57] |
LIECHTI T, ROEDERER M. OMIP-060: 30-parameter flow cytometry panel to assess T cell effector functions and regulatory T cells[J]. Cytometry A, 2019, 95(11): 1129-1134. DOI: 10.1002/cyto.a.23853.
|
[58] |
SCHERLINGER M, PAN W, HISADA R, et al. Phosphofructokinase P fine-tunes T regulatory cell metabolism, function, and stability in systemic autoimmunity[J]. Sci Adv, 2022, 8(48): eadc9657. DOI: 10.1126/sciadv.adc9657.
|
[59] |
EYQUEM J, MANSILLA-SOTO J, GIAVRIDIS T, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection[J]. Nature, 2017, 543(7643): 113-117. DOI: 10.1038/nature21405.
|
[60] |
KUOCH H, KROTOVA K, GRAHAM ML, et al. Multiplexing AAV serotype-specific neutralizing antibodies in preclinical animal models and humans[J]. Biomedicines, 2023, 11(2): 523. DOI: 10.3390/biomedicines11020523.
|
[61] |
ROTH TL, PUIG-SAUS C, YU R, et al. Reprogramming human T cell function and specificity with non-viral genome targeting[J]. Nature, 2018, 559(7714): 405-409. DOI: 10.1038/s41586-018-0326-5.
|
[62] |
DEUSE T, HU X, GRAVINA A, et al. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients[J]. Nat Biotechnol, 2019, 37(3): 252-258. DOI: 10.1038/s41587-019-0016-3.
|